Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lexicon Pharmaceuticals (LXRX) EBITDA (2024 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed EBITDA for 4 consecutive years, with -$12.7 million as the latest value for Q3 2025.

  • Quarterly EBITDA rose 80.2% to -$12.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$127.4 million through Sep 2025, up 28.0% year-over-year, with the annual reading at -$114.1 million for FY2011, 19.2% down from the prior year.
  • EBITDA for Q3 2025 was -$12.7 million at Lexicon Pharmaceuticals, down from $3.2 million in the prior quarter.
  • The five-year high for EBITDA was $3.2 million in Q2 2025, with the low at -$64.3 million in Q3 2024.